Tannock I
Cancer Res. 1983 May;43(5):2059-62.
Aziridinylbenzoquinone (AZQ), an experimental drug with good tissue penetration, was tested against aerobic and hypoxic cells of the 16/C transplantable mouse mammary tumor. The drug was given alone or with local tumor radiation to kill most of the aerobic cells. The end point of response was growth delay. AZQ gave additive effects with tumor irradiation and was equally effective against aerobic and hypoxic cells. AZQ was also given in combination with Adriamycin, since the latter drug is known to have poor penetration in solid tissue. Combined treatment led to greater antitumor effects than were obtained with maximally tolerated doses of either drug alone. Isobologram analysis of the interaction between the drugs suggested a superadditive effect, and the addition of Adriamycin had little effect on myelosuppression induced by AZQ. The combination of AZQ and Adriamycin is worthy of further study.
氮丙啶基苯醌(AZQ)是一种具有良好组织穿透性的实验性药物,针对16/C可移植小鼠乳腺肿瘤的需氧细胞和缺氧细胞进行了测试。该药物单独给药或与局部肿瘤放疗联合使用,以杀死大多数需氧细胞。反应的终点是生长延迟。AZQ与肿瘤放疗具有相加作用,对需氧细胞和缺氧细胞同样有效。AZQ还与阿霉素联合使用,因为已知后一种药物在实体组织中的穿透性较差。联合治疗比单独使用两种药物的最大耐受剂量产生了更大的抗肿瘤效果。对药物之间相互作用的等效应线图分析表明存在超相加效应,并且添加阿霉素对AZQ诱导的骨髓抑制影响很小。AZQ和阿霉素的联合值得进一步研究。